Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

Challenge: Our client was a leading UK research institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita...
Learn More

Cell and gene therapy manufacturing facility planning

Challenge: A new GMP facility for the production of investigational cell and gene therapies needed regulatory, market and technical advice before committing to a capacity expansion.
Learn More

Providing expert due diligence for the reformulation of a marketed biologic

Challenge An established European pharma company needed an opportunity assessment for a reformulation of a marketed biologic.
Learn More

Opportunity map for 3D Printing Technology for medical products

Challenge: A university commercialization institute asked Alacrita to review its technology for 3D printed, customised silicone medical products. The main task was to determine the prospective value...
Learn More

Treg cell therapy commercialization plan

Challenge: The commercialization arm of a leading university wished to identify its most promising therapeutic programs within its purview in order to allocate internal translational funding to...
Learn More

Accelerated commercial readiness strategy and launch plan

Challenge: A European immune-oncology biotech with a proprietary platform had generated a broad and deep pipeline of oncology assets, which had demonstrated an advantage due to their ability to...
Learn More

Opportunity analysis of phage technology

Challenge: An Israeli university technology transfer organization asked Alacrita to explore the different potential commercialization pathways for a novel platform technology. The overall effect of...
Learn More

Commercial infrastructure & launch plan for orphan disease drug in EU & US

Challenge: Alacrita was engaged by a biopharma company developing a therapeutic for a severe orphan disorder. With Breakthrough status designation from the FDA and a Prime designation from the EMA,...
Learn More

R&D pipeline planning for gene therapy company

Challenge: A biotechnology company developing proprietary synthetic biology technology in gene therapy expression for several clients was looking to evolve its business model. The company engaged...
Learn More

Technical & commercial review of anti-inflammatory peptide

Challenge: A university research group had discovered a new pathway for regulation of T cell trafficking in the inflammatory response. The group had also identified an anti-inflammatory peptide and...
Learn More

Market landscape exercise for three oncology therapeutics

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...
Learn More

European Payer value requirements in GAD

Challenge A privately held specialty pharmaceutical company focused in the field of psychiatry was conducting a Phase III clinical evaluation of its new formulation (one-per-day) of a commonly...
Learn More